AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.34
−0.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 54.1M | 44.5M | 57.6M | 50.6M | 47.7M |
| Cost of Revenue | 17.8M | 17.2M | 17.9M | 20.8M | 19.4M |
| Gross Profit | 36.3M | 27.4M | 39.7M | 29.8M | 28.3M |
| Operating Expenses | |||||
| R&D Expense | 15.9M | 17.2M | 20.3M | 13.1M | 17.5M |
| SG&A Expense | 73.1M | 79.8M | 50.2M | 31.8M | 52.9M |
| General & Admin Expense | 11.9M | — | — | — | — |
| Selling & Marketing Expense | 2.2M | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 89.0M | 97.0M | 70.5M | 44.9M | 70.4M |
| Cost and Expenses | 106.8M | 114.2M | 88.3M | 65.7M | 89.7M |
| Operating Income (EBIT) | (52.7M) | (69.7M) | (30.8M) | (15.1M) | (42.1M) |
| Non-Operating | |||||
| Interest Income | 882.0K | — | 3.4M | 16.3M | 99.0K |
| Interest Expense | 16.3M | 17.1M | 16.8M | 7.5M | 12.4M |
| Net Interest Income | (15.4M) | (17.1M) | (13.4M) | 8.9M | (12.3M) |
| Other Non-Op Income/Expense | (25.5M) | (14.1M) | (13.4M) | 7.5M | (12.3M) |
| Non-Operating Income (excl Interest) | 9.2M | (3.0M) | (3.4M) | (14.9M) | (99.0K) |
| EBT (Pre-Tax Income) | (78.2M) | (83.8M) | (44.2M) | (7.6M) | (54.4M) |
| Income Tax Expense | — | — | (14.0K) | 245.0K | — |
| Bottom Line | |||||
| Net Income | (78.2M) | (83.8M) | (44.1M) | (7.9M) | (54.4M) |
| Earnings from Cont. Ops | (78.2M) | (83.8M) | (44.1M) | (7.9M) | (54.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (78.2M) | (83.8M) | (44.1M) | (7.9M) | (54.4M) |
| Per Share | |||||
| Basic EPS | ($0.65) | ($0.76) | ($0.51) | ($0.13) | ($1.12) |
| Diluted EPS | ($0.65) | ($0.76) | ($0.51) | ($0.13) | ($1.12) |
| Revenue Per Share | $0.43 | $0.37 | $0.66 | $0.83 | $0.98 |
| Shares | |||||
| Basic Shares Outstanding | 125.0M | 122.0M | 86.7M | 61.3M | 48.7M |
| Diluted Shares Outstanding | 125.0M | 122.0M | 86.7M | 61.3M | 48.7M |
| Profitability Metrics | |||||
| EBITDA | (61.3M) | (66.1M) | (26.6M) | 1.2M | (39.6M) |
| D&A | 637.0K | 559.0K | 718.0K | 1.3M | 2.4M |
| EBIT | (61.9M) | (66.7M) | (27.3M) | (163.0K) | (42.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026